Severity of COVID-19 in patients with lung cancer: evidence and challenges.
Cancer patients are highly vulnerable to SARS-CoV-2 infections due to frequent contacts with the healthcare system, immunocompromised state from cancer or its therapies, supportive medications such as steroids and most importantly their advanced age and comorbidities. Patients with lung cancer have consistently been reported to suffer from an increased risk of death compared with other cancers. This is possibly due to the combination of specific pathophysiological aspects, including underlying pulmonary compromise due to smoking history and the increased specific pressures on respiratory healt... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | review |
Erscheinungsdatum: | 2021 |
Schlagwörter: | Antineoplastic Agents/therapeutic use / COVID-19/complications / COVID-19/mortality / COVID-19/physiopathology / Carcinoma / Non-Small-Cell Lung/complications / Non-Small-Cell Lung/therapy / China / Humans / Immune Checkpoint Inhibitors/therapeutic use / Italy / Lung Neoplasms/complications / Lung Neoplasms/therapy / Mortality / Netherlands / Pneumonectomy / Radiotherapy / Risk Factors / SARS-CoV-2 / Severity of Illness Index / Small Cell Lung Carcinoma/complications / Small Cell Lung Carcinoma/therapy / United Kingdom / United States / COVID-19 / lung neoplasms |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27215754 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://serval.unil.ch/notice/serval:BIB_65ACCD8023E1 |